Injectable semaglutide, sold by Novo Nordisk under the brand name Wegovy for weight loss, and tirzepatide, sold by Eli Lily as Zepbound for weight loss, generally cap out at a 15-20% body weight loss for the highest doses and 5-10% on the lower end
For tirzepatide, you start at 2.5 mg/week and increase by 2.5 mg every 4 weeks up to a maximum of 15 mg/week
REWIND Investigators Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
The effects of GLP-1 RAs on obesity are not solely due to weight loss, but some pleiotropic effects like decreased inflammation, oxidative stress, and fibrosis also play a role in some of the complications
Our top-notch professionally trained staff, ensures that MIC injections are administered safely and effectively